API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
HC-7366, a selective activator of the general control nonderepressible 2 kinases in combination with Welireg (belzutifan), Merck’s oral HIF-2α inhibitor is being investigated for the treatment of clear cell renal cell carcinoma.
Lead Product(s): HC-7366,Belzutifan
Therapeutic Area: Oncology Product Name: HC-7366
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2024
Details:
Welireg (belzutifan) is first and only hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for the adult patients with advanced renal cell carcinoma (RCC).
Lead Product(s): Belzutifan
Therapeutic Area: Oncology Product Name: Welireg
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
The collaboration aims to evaluate HiberCell's HC-7366, a selective activator of the general control nonderepressible 2 kinases in combination with Welireg (belzutifan), Merck’s oral HIF-2α inhibitor for the treatment of clear cell renal cell carcinoma.
Lead Product(s): HC-7366,Belzutifan
Therapeutic Area: Oncology Product Name: HC-7366
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 05, 2023
Details:
Welireg (belzutifan) 40 mg tablet act as the HIF-2α inhibitor, which is investigated for the treatment of adult patients with advanced renal cell carcinoma.
Lead Product(s): Belzutifan
Therapeutic Area: Oncology Product Name: Welireg
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
WELIREG (belzutifan) 40 mg tablet act as the HIF-2α inhibitor, which is investigated for the treatment of adult patients with advanced renal cell carcinoma
Lead Product(s): Belzutifan
Therapeutic Area: Oncology Product Name: Welireg
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
WELIREG is the first HIF-2α inhibitor therapy approved in the U.S. As an inhibitor of HIF-2α, WELIREG reduces transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth.
Lead Product(s): Belzutifan
Therapeutic Area: Oncology Product Name: Welireg
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2021
Details:
U.S. FDA has granted Breakthrough Therapy designation to the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482 for the treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma with nonmetastatic RCC tumors less than 3 centimeters.
Lead Product(s): Belzutifan
Therapeutic Area: Oncology Product Name: MK-6482
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020